Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated Jul 11, 2026·v1

Hyperlipidemia

Hyperlipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease, affecting over 70% of hypertensive adults. Management centers on high-intensity statins for ASCVD and high-risk primary prevention, with escalation to ezetimibe and PCSK9 inhibitors to achieve LDL-C targets (<55 mg/dL for very high risk). Severe hypertriglyceridemia (≥500 mg/dL) requires fibrates to prevent pancreatitis. Genetic syndromes like familial hypercholesterolemia (prevalence 1:250) demand cascade screening and aggressive LDL-C lowering. Primary prevention benefits from risk stratification with validated scores such as the Pooled Cohort Equations. Statins reduce all-cause mortality by 14% in primary prevention, and modern combination therapy can lower LDL-C by over 80%.

High Evidence231 references·2,861 words·12 min read·v1
HyperlipidemiaDyslipidemiaCardiologyPreventionLipid ManagementAtherosclerosis

Quick Reference

RxDrug of choiceHigh-intensity statin (atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily) for ASCVD and high-risk primary prevention.
AltAlternativesEzetimibe 10 mg daily, PCSK9 inhibitors (evolocumab 140 mg SC q2w or 420 mg monthly; inclisiran 300 mg SC at day 1, month 3, then q6mo), bempedoic acid 180 mg daily (statin intolerance), fenofibrate 160 mg daily for hypertriglyceridemia.
⊘AvoidGemfibrozil with statins (rhabdomyolysis risk); policosanol, guggulipid, and red yeast rice (no efficacy); niacin extended-release (poor tolerability, no cardiovascular benefit when added to statin).
DxTest of choiceFasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides); Lp(a) measured once; genetic testing for LDLR, APOB, PCSK9 if FH suspected (LDL-C ≥190 mg/dL).
ScKey scoreDutch Lipid Clinic Network criteria for FH (score >8 = definite FH); Pooled Cohort Equations (ACC/AHA) for 10-year ASCVD risk classification.
→When to referSuspected or confirmed FH (especially children, young adults with LDL-C ≥190 mg/dL), severe hypertriglyceridemia (≥1000 mg/dL) refractory to fibrate, statin intolerance requiring PCSK9i or bempedoic acid, need for lipoprotein apheresis.
Start high-intensity statin in all ASCVD patients and high-risk primary prevention; add ezetimibe then PCSK9i if not at goal; treat triglycerides ≥500 mg/dL with fibrate to prevent pancreatitis; screen family members when FH is confirmed.
Hyperlipidemia, an elevation of plasma lipids (LDL-C, triglycerides, or total cholesterol), is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). It is often used interchangeably with dyslipidemia, which also includes low HDL-C. Management hinges on risk stratification and lifestyle modification, with statins as first-line therapy. Severe hypertriglyceridemia (>500 mg/dL) poses acute pancreatitis risk. Global prevalence is high, with significant variations by age, sex, and geography.

Overview and Recommendations

Background

  • •Hyperlipidemia, elevation of LDL-C, triglycerides, or both, affects approximately 73% of US adults with hypertension and accounts for roughly half the population-attributable risk of myocardial infarction. Lifetime risk of cardiovascular disease at age 50 with all major risk factors present is 38% in men and 24% in women, underscoring the profound prognostic stakes.
  • •The four pillars of guideline-directed medical therapy, high-intensity , , , and , have replaced the older statin-alone paradigm following landmark trials such as IMPROVE-IT (ezetimibe add-on), FOURIER (PCSK9i), and CLEAR-Outcomes (bempedoic acid). Combined LDL-C reduction can exceed 80% with statin plus a PCSK9 inhibitor.
  • •Subendothelial retention of apolipoprotein B-containing lipoproteins (chiefly LDL and VLDL remnants) is the initiating event in atherogenesis. Oxidative modification of retained LDL triggers endothelial activation, monocyte recruitment, and foam-cell formation, the core pathophysiological cascade that progresses to plaque formation and rupture.
  • •Primary (genetic) hyperlipidemia includes familial hypercholesterolemia (FH; prevalence 1:250 for heterozygotes), familial combined hyperlipidemia (1:100), and severe hypertriglyceridemia syndromes. Secondary causes, diabetes, hypothyroidism, nephrotic syndrome, cholestasis, and medications (thiazides, retinoids, protease inhibitors), must be excluded before labeling a patient with a primary disorder.
  • •Untreated hyperlipidemia accelerates atherosclerotic progression: premature ASCVD (MI or stroke before age 55 in men, 60 in women) is a hallmark of FH. Primary prevention with statins reduces all-cause mortality by 14% (RR 0.86) and major cardiovascular events by approximately 30%, with consistent benefit across age and sex subgroups.

Evaluation

  • •Suspect hyperlipidemia in any patient with exertional dyspnea, unexplained fatigue, or a family history of premature ASCVD, especially when combined with stigmata such as xanthomas or xanthelasma on physical exam.
  • •Ask about prior lipid values, personal history of coronary artery disease, stroke, or peripheral artery disease, and any history of acute pancreatitis (marker of severe hypertriglyceridemia). Thoroughly review medications: thiazides, non-selective beta-blockers, retinoids, anabolic steroids, and protease inhibitors can all elevate lipids.
  • •Examine for tendon xanthomas, palpate the Achilles tendon while the foot is dorsiflexed; nodular thickening is pathognomonic for (FH). Also check for xanthelasma palpebrarum, arcus corneae before age 45, and eruptive xanthomas (yellow papules on extensor surfaces) that indicate severe hypertriglyceridemia.
  • •Order a fasting lipid panel as the gold-standard initial test: measure total cholesterol, LDL-C, HDL-C, and triglycerides. A non-fasting panel is acceptable for initial screening; if total cholesterol ≥200 mg/dL or HDL-C <40 mg/dL, repeat with fasting to confirm.
  • •Assess for secondary causes of hyperlipidemia with laboratory studies: TSH (hypothyroidism), HbA1c or fasting glucose (diabetes), urine protein or albumin-creatinine ratio (nephrotic syndrome), and hepatic transaminases (cholestasis, non-alcoholic fatty liver disease).
  • •Calculate 10-year ASCVD risk using the (ACC/AHA) or SCORE (ESC) for all adults aged 40-75 years without established ASCVD. Categories: low (<5%), borderline (5-7.5%), intermediate (7.5-20%), and high (≥20%).
  • •When LDL-C is ≥190 mg/dL, apply the (DLCN) criteria: assign points based on LDL-C level, family history, personal ASCVD, and physical signs. A score >8 defines definite FH, while 6-8 indicates probable FH. Genetic testing for LDLR, APOB, and PCSK9 mutations is recommended for patients with DLCN score ≥6.
  • •Measure [Lp(a)] once in adults; a level ≥50 mg/dL (or ≥125 nmol/L) is an independent risk-enhancing factor that warrants more intensive lipid lowering even if LDL-C appears well controlled.
  • •In patients with triglycerides ≥500 mg/dL, rule out familial chylomicronemia syndrome (genetic testing for LPL, APOC2, APOA5) and consider urgent therapy to prevent pancreatitis. Also check for contributory factors such as uncontrolled diabetes, excess alcohol intake, and estrogen therapy.
  • •For intermediate-risk patients (7.5-20% 10-year risk), refine risk assessment with coronary artery calcium scoring or high-sensitivity CRP (hsCRP ≥2 mg/L indicates residual inflammatory risk). A CAC score of zero can reclassify many to low risk, potentially deferring statin therapy.

Management

  • •Initiate high-intensity statin therapy immediately for all patients with established ASCVD: 40-80 mg daily or 20-40 mg daily, regardless of baseline LDL-C level. For primary prevention with LDL-C ≥190 mg/dL or 10-year risk ≥20%, start a high-intensity statin as first-line.
  • •Begin statin therapy at moderate intensity (atorvastatin 10-20 mg or rosuvastatin 5-10 mg) for primary prevention patients with intermediate risk (7.5-20%). Titrate every 4-12 weeks to achieve ≥50% LDL-C reduction.
  • •Add 10 mg daily if LDL-C remains ≥70 mg/dL (or ≥55 mg/dL in very high risk, defined as ASCVD with major risk factors or recurrent events) after 12 weeks of maximally tolerated statin. Ezetimibe provides an additional ~15-20% LDL-C reduction.
  • •For very high risk patients not at goal on statin plus ezetimibe, advance to a : 140 mg subcutaneously every 2 weeks or 420 mg monthly; or 300 mg subcutaneously at day 1, month 3, then every 6 months. These agents reduce LDL-C by approximately 50-60% on top of background therapy.
  • •For patients with statin intolerance (confirmed myalgia or CK elevation not due to other causes), consider 180 mg daily. In CLEAR-Outcomes, it reduced LDL-C by 21% and hsCRP by 22% with no excess muscle symptoms, even in patients aged ≥75 years.
  • •For severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL), start 160 mg daily to reduce pancreatitis risk. Add 2 g twice daily if triglycerides remain elevated or for residual cardiovascular risk. Do not use gemfibrozil with statins due to rhabdomyolysis risk; fenofibrate is the preferred fibrate for combination therapy.
  • •Monitor hepatic transaminases and creatine kinase at baseline and 4-12 weeks after starting or dose-escalating any statin. Do not discontinue statins for mild, non-progressive myalgias without a dechallenge-rechallenge trial; the absolute excess risk of myalgia in double-blind trials is only 2.7 per 1000 patients.
  • •Avoid ineffective or harmful therapies: policosanol, guggulipid, and red yeast rice have no proven LDL-C reduction beyond placebo. Niacin extended-release is no longer recommended due to lack of cardiovascular benefit and poor tolerability (25% discontinuation from flushing).
  • •Refer to cardiology or a lipid specialist when FH is suspected (especially in young adults or children with LDL-C ≥190 mg/dL), triglycerides remain ≥1000 mg/dL despite fibrate therapy, or when statin intolerance requires advanced therapies like PCSK9 inhibitors or bempedoic acid.
  • •For homozygous FH (HoFH) with LDL-C >100 mg/dL despite maximal pharmacotherapy, consider every 1-2 weeks; it acutely reduces LDL-C by 60-70% and, in registry data, reduces cardiovascular events by approximately 70%. Ensure cascade screening of all first-degree relatives of FH probands.

Board Review — High Yield

  • •Tendon xanthomas, Pathognomonic for familial hypercholesterolemia (FH); palpate Achilles tendon with foot dorsiflexed; indicates need for genetic testing.
  • •Dutch Lipid Clinic Network score, Definite FH: score >8 (uses LDL-C, family history, personal ASCVD, physical findings); >6 points suggests probable FH.
  • •PCSK9 inhibitors, Evolocumab 140 mg SC q2w or 420 mg monthly; achieves ~60% LDL-C reduction; inclisiran 300 mg SC at day 1, month 3, then q6mo offers siRNA-based sustained reduction.
  • •Bempedoic acid, Alternative for statin intolerance; reduces LDL-C by ~21% and hsCRP by ~22% without muscle toxicity (CLEAR-Outcomes).
  • •Lp(a), Independent risk factor measured once in adults; ≥50 mg/dL (or ≥125 nmol/L) intensifies risk; no specific approved therapy yet, but it justifies more aggressive LDL-C lowering.
  • •Severe hypertriglyceridemia, Triglycerides ≥500 mg/dL → risk of acute pancreatitis; first-line fibrate (fenofibrate 160 mg daily) plus lifestyle modification.
  • •ASCVD risk scores, Pooled Cohort Equations for 10-year risk: high (≥20%), intermediate (7.5-20%), borderline (5-7.5%), low (<5%). Consider CAC scoring for intermediate risk.
  • •Lipoprotein apheresis, For homozygous FH with LDL-C >100 mg/dL despite maximal drug therapy; reduces LDL-C by 60-70% per session every 1-2 weeks.
  • •Statins in primary prevention, JUPITER: rosuvastatin 20 mg reduced major CV events by 44% (NNT ~95) in healthy individuals with hsCRP ≥2 and LDL-C <130 mg/dL.
  • •Cascade screening, All first-degree relatives of FH probands should be screened with lipid panel and genetic testing if possible; identifies at least one affected relative in ~50% of families.

Deep Dive — Evidence Details

References

  1. [1]

    McCrindle BW, Urbina EM, Dennison BA et al.. “Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.” Circulation (2007). PMID: 17377073 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  2. [2]

    Pasupathy S, Air T, Dreyer RP et al.. “Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.” Circulation (2015). PMID: 25587100 ↗

    L2SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  3. [3]

    Wiegman A, Peterson AL, Hegele RA et al.. “Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.” Circulation (2025). PMID: 40391436 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  4. [4]

    Cooper LA, Marsteller JA, Carson KA et al.. “Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial.” Circulation (2024). PMID: 39008556 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  5. [5]

    Paramsothy P, Knopp RH, Bertoni AG et al.. “Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis).” Journal of the American College of Cardiology (2010). PMID: 20846602 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  6. [6]

    Stone GW, Selker HP, Thiele H et al.. “Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials.” Journal of the American College of Cardiology (2016). PMID: 27056772 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  7. [7]

    Cho L, Davis M, Elgendy I et al.. “Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2020). PMID: 32439010 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention
  8. [8]

    Ridker PM, Lei L, Louie MJ et al.. “Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.” Circulation (2023). PMID: 37929602 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Complications
  9. [9]

    Boyer TM, Barrett RB, Xiong C et al.. “Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.” Circulation (2025). PMID: 41697979 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  10. [10]

    Mosley JD, Benson MD, Smith JG et al.. “Probing the Virtual Proteome to Identify Novel Disease Biomarkers.” Circulation (2018). PMID: 30571344 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  11. [11]

    Jayaraman R, Reinier K, Nair S et al.. “Risk Factors of Sudden Cardiac Death in the Young: Multiple-Year Community-Wide Assessment.” Circulation (2017). PMID: 29269388 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Prognosis and Natural History
  12. [12]

    Covani M, Niccoli G, Fujimoto D et al.. “Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome: An Optical Coherence Tomography Analysis.” Journal of the American College of Cardiology (2025). PMID: 40634017 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications
  13. [13]

    Elgendy IY, Gad MM, Mahmoud AN et al.. “Acute Stroke During Pregnancy and Puerperium.” Journal of the American College of Cardiology (2020). PMID: 31948647 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention
  14. [14]

    Krishnan P, Farhan S, Schneider P et al.. “Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.” Journal of the American College of Cardiology (2022). PMID: 36137674 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  15. [15]

    DeFilippis EM, Singh A, Divakaran S et al.. “Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction.” Journal of the American College of Cardiology (2018). PMID: 29535062 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Prognosis and Natural History
  16. [16]

    Ahn JM, Lee KH, Yoo SY et al.. “Prognosis of Variant Angina Manifesting as Aborted Sudden Cardiac Death.” Journal of the American College of Cardiology (2016). PMID: 27386766 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  17. [17]

    Martin SS, Niles JK, Kaufman HW et al.. “Lipid distributions in the Global Diagnostics Network across five continents.” European heart journal (2023). PMID: 37392135 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy
  18. [18]

    Ditkofsky N, Hanna T. “Images in Clinical Medicine. Spontaneous Retropharyngeal Hematoma.” The New England journal of medicine (2016). PMID: 26789902 ↗

    L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  19. [19]

    Otto CM, Newby DE, Hillis GS. “Calcific Aortic Stenosis: A Review.” JAMA (2024). PMID: 39527048 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
  20. [20]

    Tilg H, Petta S, Stefan N et al.. “Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.” JAMA (2026). PMID: 41212550 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  21. [21]

    McFarland R, Hyslop LA, Feeney C et al.. “Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.” The New England journal of medicine (2025). PMID: 40689593 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention
  22. [22]

    Bogner B, Jung M, Reisert M et al.. “Opportunistic screening for incident cardiometabolic disease in metabolically healthy non-obese individuals: a prospective cohort study.” Cardiovascular diabetology (2026). PMID: 42387503 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History
  23. [23]

    Wabnitz AM. “Management of Large Artery Atherosclerosis.” Continuum (Minneapolis, Minn.) (2026). PMID: 42233827 ↗

    L5CASE_REPORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  24. [24]

    Qiao Y, Suri FK, Zhang Y et al.. “Racial Differences in Prevalence and Risk for Intracranial Atherosclerosis in a US Community-Based Population.” JAMA cardiology (2017). PMID: 29094154 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy
  25. [25]

    van Rosendael AR, Narula J, Lin FY et al.. “Association of High-Density Calcified 1K Plaque With Risk of Acute Coronary Syndrome.” JAMA cardiology (2020). PMID: 31968065 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment
  26. [26]

    O'Connor KD, Brophy T, Fonarow GC et al.. “Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure.” Circulation. Heart failure (2020). PMID: 32207996 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  27. [27]

    Yeh CF, Ianalieva L, Wong HK et al.. “Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.” Journal of biomedical science (2026). PMID: 42069590 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation
  28. [28]

    Atalla M, Gupta V, Khalid M et al.. “Cardiology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974015 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation
  29. [29]

    Lei J, Lu X, Liang Q. “Lipemic anterior chamber mimicking uveitis in severe hypertriglyceridemia: a case report and literature review.” BMC ophthalmology (2026). PMID: 42087131 ↗

    L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Complications
  30. [30]

    Alzoubi M, Omar Saleh A, Omari FA et al.. “Asymptomatic gallstones: Cumulative incidence proportion, incidence rate, and risk factors for symptoms development: Systematic review and meta-analysis.” PloS one (2026). PMID: 41886405 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation
  31. [31]

    Kayani AMA, Umar MF, Navarro-Martinez D et al.. “Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.” Vascular diseases (Paris, France) (2026). PMID: 41763910 ↗

    L5SR_OBSCited in: Definition, Classification and Nomenclature
  32. [32]

    Tang L, He Y, Qiao Z et al.. “Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.” Frontiers in immunology (2026). PMID: 42344901 ↗

    L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  33. [33]

    Mahmoodi BK, Cushman M, Anne Næss I et al.. “Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective Studies.” Circulation (2016). PMID: 27831499 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications
  34. [34]

    Purnell JQ, Zinman B, Brunzell JD. “The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.” Circulation (2012). PMID: 23212717 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  35. [35]

    Xie X, Shi X, Zhang Y et al.. “Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.” Journal of the American College of Cardiology (2025). PMID: 40167414 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  36. [36]

    Haine A, Kavanagh S, Berger JS et al.. “Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.” Journal of the American College of Cardiology (2020). PMID: 32057375 ↗

    L2RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History
  37. [37]

    Boccara F, Kumar PN, Caramelli B et al.. “Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.” Journal of the American College of Cardiology (2020). PMID: 32234462 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  38. [38]

    Shaw AT, Bauer TM, de Marinis F et al.. “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.” The New England journal of medicine (2020). PMID: 33207094 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  39. [39]

    Ridker PM, Danielson E, Fonseca FA et al.. “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.” The New England journal of medicine (2008). PMID: 18997196 ↗

    L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History
  40. [40]

    Basaria S, Coviello AD, Travison TG et al.. “Adverse events associated with testosterone administration.” The New England journal of medicine (2010). PMID: 20592293 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  41. [41]

    Hudes G, Carducci M, Tomczak P et al.. “Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.” The New England journal of medicine (2007). PMID: 17538086 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  42. [42]

    Rossebø AB, Pedersen TR, Boman K et al.. “Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.” The New England journal of medicine (2008). PMID: 18765433 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  43. [43]

    Kashani A, Phillips CO, Foody JM et al.. “Risks associated with statin therapy: a systematic overview of randomized clinical trials.” Circulation (2006). PMID: 17159064 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications
  44. [44]

    Hong KN, Fuster V, Rosenson RS et al.. “How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD.” Journal of the American College of Cardiology (2017). PMID: 29050566 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications
  45. [45]

    Miller JD, Aronis KN, Chrispin J et al.. “Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation.” Journal of the American College of Cardiology (2015). PMID: 26718677 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications
  46. [46]

    Chou R, Dana T, Blazina I et al.. “Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2016). PMID: 27838722 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  47. [47]

    Machline-Carrion MJ, Soares RM, Damiani LP et al.. “Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial.” JAMA cardiology (2019). PMID: 30942842 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  48. [48]

    Ikramuddin S, Korner J, Lee WJ et al.. “Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.” JAMA (2013). PMID: 23736733 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  49. [49]

    Kempen JH, Altaweel MM, Holbrook JT et al.. “Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.” JAMA (2017). PMID: 28477440 ↗

    L2RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  50. [50]

    Birger M, Kaldjian AS, Roth GA et al.. “Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016.” Circulation (2021). PMID: 33926203 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  51. [51]

    Saha P, Potiny P, Rigdon J et al.. “Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease.” Circulation (2019). PMID: 30813762 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  52. [52]

    DeCarlo C, Latz CA, Boitano LT et al.. “Prognostication of Asymptomatic Penetrating Aortic Ulcers: A Modern Approach.” Circulation (2021). PMID: 34376058 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, History and Evolution of Treatment, Complications, Prognosis and Natural History
  53. [53]

    Caleyachetty R, Thomas GN, Toulis KA et al.. “Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women.” Journal of the American College of Cardiology (2017). PMID: 28911506 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications
  54. [54]

    Lee HH, Crawford EB, Cho SMJ et al.. “Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.” Journal of the American College of Cardiology (2025). PMID: 41295934 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy
  55. [55]

    Sinha A, Ning H, Carnethon MR et al.. “Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure: A Population-Based Cohort Study From the Lifetime Risk Pooling Project.” Circulation. Heart failure (2021). PMID: 33761754 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification
  56. [56]

    Markus MRP, Ittermann T, Mariño Coronado J et al.. “Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.” European heart journal (2025). PMID: 40320753 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Complications
  57. [57]

    Wu J, Zafar MA, Liu Y et al.. “Fate of the unoperated ascending thoracic aortic aneurysm: three-decade experience from the Aortic Institute at Yale University.” European heart journal (2023). PMID: 36994934 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  58. [58]

    Rafiee M, Mehmandoost S, Harandi F et al.. “Prevalence of Hypertension, Diabetes, Obesity, and High Cholesterol Among Older People Living With HIV: A Systematic Review and Meta-Analysis.” AIDS research and treatment (2026). PMID: 42358331 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors
  59. [59]

    Magnussen C, Alegre-Diaz J, Al-Nasser LA et al.. “Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.” The New England journal of medicine (2025). PMID: 40162648 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Complications, Prognosis and Natural History
  60. [60]

    Wang N, Li M, Lu M et al.. “Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review.” Medicine (2026). PMID: 42332507 ↗

    L5SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy
  61. [61]

    Sadeghi E, Kozlov M, Hasan N et al.. “Associations between psychiatric disorders and medication use, and retinal occlusion: a large-scale retrospective cohort study.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42371026 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History
  62. [62]

    Thangjui S, Knutsen K, Hollowell B et al.. “Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42370998 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  63. [63]

    Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy
  64. [64]

    Liu M, Marinacci LX, Joynt Maddox KE et al.. “Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors.” JAMA cardiology (2025). PMID: 40163358 ↗

    L2OTHERCited in: Epidemiology and Risk Factors
  65. [65]

    Oseran AS, Sun T, Wadhera RK. “Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status.” JAMA cardiology (2022). PMID: 35648424 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy
  66. [66]

    Tung EL, Wroblewski KE, Makelarski JA et al.. “Childhood Parental Incarceration and Adult-Onset Hypertension and Cardiovascular Risk.” JAMA cardiology (2023). PMID: 37647038 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History
  67. [67]

    Gong J, Vaduganathan M, Wadhera RK. “Chronic Kidney Disease Prevalence and Awareness Among US Adults.” JAMA cardiology (2026). PMID: 41205219 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  68. [68]

    Brandt EJ, Chang T, Leung C et al.. “Food Insecurity Among Individuals With Cardiovascular Disease and Cardiometabolic Risk Factors Across Race and Ethnicity in 1999-2018.” JAMA cardiology (2022). PMID: 36170056 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Complications
  69. [69]

    Whelton SP, McEvoy JW, Shaw L et al.. “Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors.” JAMA cardiology (2020). PMID: 32936272 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification
  70. [70]

    Bansal N, Katz R, Robinson-Cohen C et al.. “Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies.” JAMA cardiology (2017). PMID: 28002548 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Special Populations and Prevention
  71. [71]

    Honigberg MC, Zekavat SM, Aragam K et al.. “Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.” JAMA (2019). PMID: 31738818 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  72. [72]

    Aggarwal R, Yeh RW, Joynt Maddox KE et al.. “Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020.” JAMA (2023). PMID: 36871237 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment
  73. [73]

    Record NB, Onion DK, Prior RE et al.. “Community-wide cardiovascular disease prevention programs and health outcomes in a rural county, 1970-2010.” JAMA (2015). PMID: 25585326 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  74. [74]

    Gelfand JM, Neimann AL, Shin DB et al.. “Risk of myocardial infarction in patients with psoriasis.” JAMA (2006). PMID: 17032986 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Prognosis and Natural History
  75. [75]

    McTigue K, Larson JC, Valoski A et al.. “Mortality and cardiac and vascular outcomes in extremely obese women.” JAMA (2006). PMID: 16820550 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History
  76. [76]

    Qin H, Tromp J, Ter Maaten JM et al.. “Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women.” JACC. Heart failure (2024). PMID: 39708029 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment, Complications
  77. [77]

    Xu Y, Yang H, Xu Q et al.. “Distinct From the Adult Paradigm: Re-Evaluate the Pathophysiological and Therapeutic Framework in Children and Adolescent Hyperlipidaemia.” Current obesity reports (2026). PMID: 42287583 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
  78. [78]

    Wang S, Wang L, Shi D et al.. “Relationship between hyperlipidemia and lumbar disc degeneration in patients with low back pain: an observational retrospective study.” Frontiers in physiology (2026). PMID: 42318506 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History
  79. [79]

    Yang W, Hu W, Pan Y et al.. “Impact of preoperative dual antiplatelet therapy vs. aspirin monotherapy on perioperative outcomes in carotid endarterectomy patients: a retrospective cohort study.” International journal of clinical pharmacy (2026). PMID: 42171869 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Complications
  80. [80]

    Piña IL, Zheng Q, She L et al.. “Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).” Circulation (2018). PMID: 29459462 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Prognosis and Natural History
  81. [81]

    Ghattas A, Griffiths HR, Devitt A et al.. “Monocytes in coronary artery disease and atherosclerosis: where are we now?” Journal of the American College of Cardiology (2013). PMID: 23973684 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  82. [82]

    Bravata DM, Smith-Spangler C, Sundaram V et al.. “Using pedometers to increase physical activity and improve health: a systematic review.” JAMA (2007). PMID: 18029834 ↗

    L2SR_OBSCited in: Pathophysiology and Mechanism, Clinical Presentation
  83. [83]

    Lee JK, Grace KA, Taylor AJ. “Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.” JAMA (2006). PMID: 17101639 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  84. [84]

    Gu H, Wen J, Liu Y et al.. “SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure.” Circulation (2026). PMID: 42170742 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  85. [85]

    Drechsler M, Megens RT, van Zandvoort M et al.. “Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis.” Circulation (2010). PMID: 20956207 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Complications
  86. [86]

    Li X, Zhu M, Penfold ME et al.. “Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue.” Circulation (2013). PMID: 24374972 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  87. [87]

    Koskinas KC, Feldman CL, Chatzizisis YS et al.. “Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study.” Circulation (2010). PMID: 20439786 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  88. [88]

    Lerman JB, Joshi AA, Chaturvedi A et al.. “Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.” Circulation (2017). PMID: 28483812 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
  89. [89]

    Seehaus S, Shahzad K, Kashif M et al.. “Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.” Circulation (2009). PMID: 19687358 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  90. [90]

    Xiao H, Lu M, Lin TY et al.. “Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility.” Circulation (2013). PMID: 23838163 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  91. [91]

    Alvi RM, Neilan AM, Tariq N et al.. “Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.” Journal of the American College of Cardiology (2018). PMID: 30049313 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  92. [92]

    Jaguan D, Gratz BW, Jaguan SI et al.. “Treatment of Generalized Granuloma Annulare with JAK Inhibitors: Systematic Review.” Clinical, cosmetic and investigational dermatology (2026). PMID: 42111237 ↗

    L2SR_OBSCited in: Pathophysiology and Mechanism, Complications
  93. [93]

    Oshitari T. “Pathogenesis of Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with COVID-19.” International journal of molecular sciences (2026). PMID: 41898506 ↗

    L5CASE_REPORTCited in: Pathophysiology and Mechanism
  94. [94]

    King WC, Hinerman AS, Belle SH et al.. “Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes.” JAMA (2018). PMID: 30326125 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  95. [95]

    Wijeysundera HC, Machado M, Farahati F et al.. “Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005.” JAMA (2010). PMID: 20460623 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management
  96. [96]

    Hall JE, Omoto ACM, do Carmo JM et al.. “Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.” Clinical science (London, England : 1979) (2026). PMID: 42340064 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications
  97. [97]

    Foroohar T, Berk-Krauss J, Caplan AS et al.. “Granuloma Annulare: An Updated Review of Epidemiology, Molecular Pathogenesis, and Management.” Journal of the American Academy of Dermatology (2026). PMID: 42320859 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy
  98. [98]

    Subauste CS. “Advances in the Role of the CD40-CD154 Pathway in the Pathogenesis of Diabetic Retinopathy.” International journal of molecular sciences (2026). PMID: 42123447 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  99. [99]

    Jovanovic K, Jovandaric MZ, Jovanovic D et al.. “Altered Lipid Profile and Oxidative Stress During Pregnancy: Impact on the Fetus and Risk of Metabolic Disorders in Adulthood.” International journal of molecular sciences (2026). PMID: 42123329 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Special Populations and Prevention
  100. [100]

    Lin L, Zi S, Zhang G et al.. “Advances in the pathogenesis of MASLD and its association with neutrophils.” Frontiers in medicine (2026). PMID: 41889493 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  101. [101]

    Kaplan R, Berni M, Caliogna L et al.. “Pathogenesis of Shoulder Calcific Tendinopathy.” International journal of molecular sciences (2026). PMID: 41828406 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  102. [102]

    Zhang M, Liu WL, Xu G et al.. “Hyperlipidemia in membranous nephropathy.” Clinical kidney journal (2026). PMID: 41822057 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  103. [103]

    Hsu JJ, Li Q, Tintut Y et al.. “Considerations in the Use of Mouse Models of Vascular and Valvular Calcification.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41739911 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  104. [104]

    Navar-Boggan AM, Peterson ED, D'Agostino RB et al.. “Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease.” Circulation (2015). PMID: 25623155 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  105. [105]

    Pande RL, Perlstein TS, Beckman JA et al.. “Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004.” Circulation (2008). PMID: 18559705 ↗

    L4OTHERCited in: Clinical Presentation
  106. [106]

    Fracassi F, Crea F, Sugiyama T et al.. “Healed Culprit Plaques in Patients With Acute Coronary Syndromes.” Journal of the American College of Cardiology (2019). PMID: 31072568 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  107. [107]

    Kanner AM, Bicchi MM. “Antiseizure Medications for Adults With Epilepsy: A Review.” JAMA (2022). PMID: 35380580 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  108. [108]

    Choi SI, Heo Y, Ryu SW et al.. “Safety, Efficacy, and Quality of Life Outcomes of Bariatric and Metabolic Surgery in Korea: A Prospective Multicenter Cohort Study.” Obesity surgery (2026). PMID: 42098468 ↗

    L2COHORTCited in: Clinical Presentation
  109. [109]

    Lu Z, Zong D, Yang Z et al.. “Risk factors for rebleeding in acute lower gastrointestinal bleeding: a systematic review and meta-analysis.” International journal of colorectal disease (2026). PMID: 42287444 ↗

    L1SR_OBSCited in: Clinical Presentation, Acute and Initial Management
  110. [110]

    Tu Y, Sun Y, Zhu M et al.. “Bilateral extensive adult-onset limbal xanthogranuloma invading the deep corneal stroma: a case report and literature review.” Frontiers in medicine (2026). PMID: 42369137 ↗

    L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment
  111. [111]

    Laffin LJ, Bruemmer D, Garcia M et al.. “Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.” Journal of the American College of Cardiology (2022). PMID: 36351465 ↗

    L1RCTCited in: Diagnosis and Workup, History and Evolution of Treatment, Complications
  112. [112]

    Miller JD, Weiss RM, Serrano KM et al.. “Lowering plasma cholesterol levels halts progression of aortic valve disease in mice.” Circulation (2009). PMID: 19433756 ↗

    L5OTHERCited in: Diagnosis and Workup, Complications
  113. [113]

    Roifman I, Therrien J, Ionescu-Ittu R et al.. “Coarctation of the aorta and coronary artery disease: fact or fiction?” Circulation (2012). PMID: 22675158 ↗

    L2OTHERCited in: Diagnosis and Workup
  114. [114]

    Masri A, Kalahasti V, Svensson LG et al.. “Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With a Trileaflet Aortic Valve and a Dilated Aorta.” Circulation (2016). PMID: 27770001 ↗

    L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
  115. [115]

    Miller TD, Redberg RF, Wackers FJ. “Screening asymptomatic diabetic patients for coronary artery disease: why not?” Journal of the American College of Cardiology (2006). PMID: 16904546 ↗

    L5OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  116. [116]

    Cavusoglu E, Kornecki E, Sobocka MB et al.. “Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis.” Journal of the American College of Cardiology (2007). PMID: 17964041 ↗

    L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
  117. [117]

    Civeira F, Jarauta E, Cenarro A et al.. “Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.” Journal of the American College of Cardiology (2008). PMID: 19007590 ↗

    L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
  118. [118]

    Zeng Y, Sun Y. “Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators.” BMC women's health (2026). PMID: 41952141 ↗

    L2COHORTCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
  119. [119]

    Chiang LH, Tsai PH, Chen YF et al.. “Real-World Safety and Retention of Tofacitinib in Elderly Versus Non-elderly Patients With Rheumatoid Arthritis: A Retrospective Cohort Study in Taiwan.” International journal of rheumatic diseases (2026). PMID: 42177625 ↗

    L2COHORTCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  120. [120]

    Zhou X, Yang C, Zou T et al.. “Shared Genetic Risk Between Acute Pancreatitis and Metabolic Syndrome Converges on a BCAT1-Positive Fibroblast Subpopulation and MAPK14-Driven Inflammation.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 42402174 ↗

    L2OTHERCited in: Diagnosis and Workup, Acute and Initial Management
  121. [121]

    Qin Y, Hong Y, Ning L et al.. “Subtype-Specific Associations Between Hyperlipidemia and Age-Related Cataract: A Clinic-Based Cross-Sectional Study.” Clinical interventions in aging (2026). PMID: 42333214 ↗

    L4OTHERCited in: Diagnosis and Workup
  122. [122]

    Li S, Wen ZQ, Yan P. “Zexie decoction alleviates hyperlipidemia through modulation of the PPAR signaling pathway and lysophospholipid metabolism.” Pharmaceutical biology (2026). PMID: 42295113 ↗

    L5OTHERCited in: Diagnosis and Workup
  123. [123]

    Huang X, Lu N, Yu H et al.. “The impact of 1-hour plasma glucose on the metabolic characteristics and pregnancy outcomes in polycystic ovary syndrome.” Nutrition & diabetes (2026). PMID: 42285965 ↗

    L2OTHERCited in: Diagnosis and Workup
  124. [124]

    Yin WL, Peng L, Zhang JH et al.. “Hyperlipid-Related Alzheimer's Disease: Potential Role of CircUCK2/miR-24-3p/p38 Axis in Neuronal Damage.” Comprehensive Physiology (2026). PMID: 42281258 ↗

    L3OTHERCited in: Diagnosis and Workup
  125. [125]

    Nagaoka M, Nagaoka K, Kajitani N et al.. “Serum Mac-2 Binding Protein Glycan Isomer and Cerebral White Matter Injury in Older Adults: A Hepatic-Cerebral Link.” Hepatology research : the official journal of the Japan Society of Hepatology (2026). PMID: 42246447 ↗

    L4OTHERCited in: Diagnosis and Workup
  126. [126]

    Zhong XY, Peng R, Deng Y et al.. “Drinking Patterns and CT/MRI Feature-Based Nomogram Models Can More Accurately Predict Acute Alcoholic Pancreatitis Recurrence.” Alcohol, clinical & experimental research (2026). PMID: 42246257 ↗

    L3OTHERCited in: Diagnosis and Workup
  127. [127]

    Li W, Fredriksson M, Dernroth DN et al.. “Sex differences in iron stores and associations of body iron with cardiovascular risk factors in the middle-aged general population.” Frontiers in endocrinology (2026). PMID: 42222086 ↗

    L4OTHERCited in: Diagnosis and Workup
  128. [128]

    Ata HS, Abd El-Rady NM, Gomaa AMS et al.. “Neurodegenerative and Glial Physiology in Diabetic Retinopathy: Dissociated Effects of Forskolin on Neuronal Survival and Glial Activation.” Biomedicines (2026). PMID: 42193428 ↗

    L5OTHERCited in: Diagnosis and Workup
  129. [129]

    Ridker PM, MacFadyen J, Cressman M et al.. “Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.” Journal of the American College of Cardiology (2010). PMID: 20206456 ↗

    L1TRIAL_NONRANDOMCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  130. [130]

    Zhang D, Jiang X, Fang P et al.. “Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice.” Circulation (2009). PMID: 19858416 ↗

    L5OTHERCited in: Severity Staging and Risk Stratification
  131. [131]

    Fu J, Zhou Y, Zhang F et al.. “Risk factors for postoperative venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 41613334 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification
  132. [132]

    Wu HL, Chen JT, Cata JP et al.. “Preoperative proprotein convertase subtilisin/kexin type 9 inhibitors versus statins and postoperative adverse events in hyperlipidemia: A nationwide, active-comparator cohort study.” Atherosclerosis (2026). PMID: 42048760 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification, Prognosis and Natural History
  133. [133]

    Wolff K, Gumin D, Shqara RA et al.. “Risk factors and predictive modeling for occult endometrial cancer in women with atypical hyperplasia: a retrospective study.” Archives of gynecology and obstetrics (2026). PMID: 41611996 ↗

    L3COHORTCited in: Severity Staging and Risk Stratification
  134. [134]

    Zhong W, Jiang F, Wang H et al.. “Polypharmacy, determinants, and adverse outcomes in elderly patients with heart failure: a multicenter retrospective cohort study of 7,361 subjects.” BMC geriatrics (2026). PMID: 41588351 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  135. [135]

    Li J, Wang Y, Chen Z et al.. “Association between autologous blood transfusion and serum creatinine in patients with acute Stanford-A aortic dissection based on a retrospective study.” BMC anesthesiology (2026). PMID: 41566236 ↗

    L3COHORTCited in: Severity Staging and Risk Stratification
  136. [136]

    Zhang Y, Zhang X, Song H et al.. “Predicting short-term composite outcome risk in heart failure patients using a machine learning model incorporating UHR: a retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42305866 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment
  137. [137]

    Shen Q, Zhou S, Ouyang X et al.. “Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: a real-world cohort study.” Heart & lung : the journal of critical care (2026). PMID: 42030746 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  138. [138]

    Cheng ZT, Wang JL, Zhao YB et al.. “Association Between the Lactate-to-Albumin Ratio and ICU/In-Hospital Mortality in Critically Ill Patients With Comorbid Type 2 Diabetes Mellitus : A Cohort Study Utilizing the MIMIC-IV Database.” Emergency medicine international (2026). PMID: 41982276 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  139. [139]

    Vega RB, O'Mahony G, Barbour AM et al.. “Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.” Circulation (2026). PMID: 42137960 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  140. [140]

    Ballantyne CM, Gaudet D, Rosenson RS et al.. “Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.” Journal of the American College of Cardiology (2025). PMID: 40099777 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  141. [141]

    McKenney JM, Farnier M, Lo KW et al.. “Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.” Journal of the American College of Cardiology (2006). PMID: 16630994 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  142. [142]

    Rosenson RS, Gaudet D, Hegele RA et al.. “Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38809174 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  143. [143]

    Blom DJ, Hala T, Bolognese M et al.. “A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.” The New England journal of medicine (2014). PMID: 24678979 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  144. [144]

    Ballantyne CM, Vasas S, Azizad M et al.. “Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38804517 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  145. [145]

    Ridker PM, Tardif JC, Amarenco P et al.. “Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.” The New England journal of medicine (2017). PMID: 28304227 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  146. [146]

    Puzziferri N, Roshek TB, Mayo HG et al.. “Long-term follow-up after bariatric surgery: a systematic review.” JAMA (2014). PMID: 25182102 ↗

    L2SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  147. [147]

    Berthold HK, Unverdorben S, Degenhardt R et al.. “Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.” JAMA (2006). PMID: 16705107 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  148. [148]

    Smilowitz NR, Mega JL, Berger JS. “Duration of anticoagulation for venous thromboembolic events.” Circulation (2014). PMID: 25539522 ↗

    L4CASE_REPORTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  149. [149]

    Schwab RD, Degaramo D, Hong SJ et al.. “Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development.” Circulation (2025). PMID: 41268661 ↗

    L5OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
  150. [150]

    Al Mheid I, Quyyumi AA. “Vitamin D and Cardiovascular Disease: Controversy Unresolved.” Journal of the American College of Cardiology (2017). PMID: 28662812 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  151. [151]

    Moccetti F, Brown E, Xie A et al.. “Myocardial Infarction Produces Sustained Proinflammatory Endothelial Activation in Remote Arteries.” Journal of the American College of Cardiology (2018). PMID: 30139430 ↗

    L5OTHERCited in: Acute and Initial Management
  152. [152]

    Hsu J, Price M, Huang J et al.. “Unintended consequences of caps on Medicare drug benefits.” The New England journal of medicine (2006). PMID: 16738271 ↗

    L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
  153. [153]

    Jackevicius CA, Tu JV, Ross JS et al.. “Use of ezetimibe in the United States and Canada.” The New England journal of medicine (2008). PMID: 18375999 ↗

    L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
  154. [154]

    Meng X, Ou Y, Mao J et al.. “LDAR outperforms other albumin-derived indices in predicting 28-day ICU mortality in critically ill myocardial infarction patients: a two-cohort study.” Frontiers in medicine (2026). PMID: 42221102 ↗

    L2COHORTCited in: Acute and Initial Management
  155. [155]

    Whitmer RA, Karter AJ, Yaffe K et al.. “Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.” JAMA (2009). PMID: 19366776 ↗

    L2OTHERCited in: Acute and Initial Management
  156. [156]

    Choi H, Choi J, Maksatbekov C et al.. “Predictors of in-hospital case-fatality in patients with stroke at the National Hospital of the Kyrgyz Republic: a retrospective cohort study.” BMC neurology (2026). PMID: 42216139 ↗

    L2COHORTCited in: Acute and Initial Management
  157. [157]

    Devanita S LA, Adhyatma IGR, Cahya KKD. “Risk factors of cerebral vasospasm associated with ruptured arterio-venous malformation: A systematic review and meta-analysis.” Journal of cerebrovascular and endovascular neurosurgery (2026). PMID: 42374993 ↗

    L2SR_OBSCited in: Acute and Initial Management
  158. [158]

    Liao HW, Luyckx V, Ostermann M et al.. “Severe Pregnancy-Associated Acute Kidney Injury and Maternal Vulnerability.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 42406539 ↗

    L2OTHERCited in: Acute and Initial Management
  159. [159]

    Jiang Q, Wang R, He Y et al.. “Construction and Validation of a 90-Day Mortality Risk Prediction Model Based on Interpretable Machine Learning for Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy.” Journal of clinical medicine (2026). PMID: 42355869 ↗

    L2OTHERCited in: Acute and Initial Management
  160. [160]

    Foody JM, Shah R, Galusha D et al.. “Statins and mortality among elderly patients hospitalized with heart failure.” Circulation (2006). PMID: 16490817 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention
  161. [161]

    Bair TL, Muhlestein JB, May HT et al.. “Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry.” Circulation (2007). PMID: 17846308 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  162. [162]

    Piazza G, Campia U, Hurwitz S et al.. “Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.” Journal of the American College of Cardiology (2020). PMID: 33121712 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History
  163. [163]

    Allard NAE, Janssen L, Aussieker T et al.. “Moderate Intensity Exercise Training Improves Skeletal Muscle Performance in Symptomatic and Asymptomatic Statin Users.” Journal of the American College of Cardiology (2021). PMID: 34794683 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  164. [164]

    Mancini GBJ, Lincoff AM, Goldberg AC et al.. “Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.” Journal of the American Heart Association (2026). PMID: 42333640 ↗

    L1RCTCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention
  165. [165]

    Reges O, Greenland P, Dicker D et al.. “Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality.” JAMA (2018). PMID: 29340677 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  166. [166]

    Wu J, Zhang F, Li Q et al.. “Predictors of difficult vascular access during transradial neurointervention: a retrospective study.” Revista da Associacao Medica Brasileira (1992) (2026). PMID: 42339907 ↗

    L2COHORTCited in: Long-term Guideline-Directed Therapy
  167. [167]

    Duan Y, Pan Z, Gu J et al.. “Disparities in anticoagulation therapy for older adults with non-valvular atrial fibrillation: a comparative study of urban and suburban communities.” BMC geriatrics (2026). PMID: 42420880 ↗

    L4OTHERCited in: Long-term Guideline-Directed Therapy
  168. [168]

    Papatheodoridis G, Buti M, Yilmaz Y et al.. “Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes.” Journal of gastroenterology and hepatology (2026). PMID: 42419754 ↗

    L4OTHERCited in: Long-term Guideline-Directed Therapy
  169. [169]

    Yu M, Lei C, Zou T et al.. “Multidimensional factors influencing the recovery trajectory of residual dizziness after successful canalith repositioning in benign paroxysmal positional vertigo: an ordered logistic regression analysis.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026). PMID: 42402503 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  170. [170]

    Jafari EA. “Hypertension among Middle Eastern and North African adults residing in the United States: addressing equity in health research representation using the All of Us Research Program, 2000-2024.” Frontiers in medicine (2026). PMID: 42383063 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  171. [171]

    Dabour MS, Shaaban A, Duprez DA et al.. “Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?” Breast cancer research and treatment (2026). PMID: 42329476 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  172. [172]

    Peng L, Zhu N, Zhang CJ et al.. “Beyond lipid-lowering effects: Challenges and insights in fenofibrate repurposing for oncology.” Life sciences (2026). PMID: 42302925 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy
  173. [173]

    Han X, Hopkins SC, Zhang Z et al.. “The Economic Impact of Cumulative Metabolic Comorbidity Burden in Schizophrenia: A Claims-Based Analysis of Medical Costs in the United States.” Neurology and therapy (2026). PMID: 42301550 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  174. [174]

    Zhang X, Xu H, Yu J et al.. “Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection.” Circulation (2023). PMID: 37232170 ↗

    L5OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History
  175. [175]

    Kim YH, Park DW, Lee SW et al.. “Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.” Circulation (2009). PMID: 19620506 ↗

    L2OTHERCited in: Interventional and Device Therapy, Special Populations and Prevention
  176. [176]

    Koupenova M, Johnston-Cox H, Vezeridis A et al.. “A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.” Circulation (2011). PMID: 22144568 ↗

    L5OTHERCited in: Interventional and Device Therapy
  177. [177]

    Thomas M, Schymik G, Walther T et al.. “One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.” Circulation (2011). PMID: 21747054 ↗

    L4OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History
  178. [178]

    Yu E, Calvert PA, Mercer JR et al.. “Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans.” Circulation (2013). PMID: 23841983 ↗

    L4OTHERCited in: Interventional and Device Therapy
  179. [179]

    Molony DS, Hung O, Corban M et al.. “A randomized prospective study investigating the relationship between post-PCI wall shear stress and 12-month neointimal healing: The SHEAR-STENT study.” Cardiovascular revascularization medicine : including molecular interventions (2025). PMID: 41285658 ↗

    L1RCTCited in: Interventional and Device Therapy
  180. [180]

    Önder R, Geebelen G, Scherrenberg M et al.. “The impact of cardiac rehabilitation on atrial fibrillation recurrence after pulmonary vein isolation: results of a large retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 41674867 ↗

    L2COHORTCited in: Interventional and Device Therapy
  181. [181]

    Zhu Q, Zhang Y, Liu J et al.. “Clinical validation study of a novel prognostic risk prediction model (CHIP Score) for interventional therapy in patients with NSTE-ACS-a single-center retrospective cohort study based on 348 patients.” BMC cardiovascular disorders (2026). PMID: 41507846 ↗

    L2COHORTCited in: Interventional and Device Therapy
  182. [182]

    Li W, Zhang G, Chen Y et al.. “Incidence and risk factors of posttransplant diabetes mellitus in lung transplant recipients: a retrospective cohort study.” Journal of thoracic disease (2025). PMID: 41376958 ↗

    L2COHORTCited in: Interventional and Device Therapy
  183. [183]

    Lin X, Wang Y, Tan S et al.. “Long-term safety, effectiveness, and cost of rapamycin- vs. everolimus-eluting stents in acute coronary syndrome: a real-world cohort study.” International journal of clinical pharmacy (2025). PMID: 41369785 ↗

    L2COHORTCited in: Interventional and Device Therapy
  184. [184]

    Yen WC, Yang MH, Weng TH et al.. “Dialysis and the risk of early urological cancer: A nationwide population-based cohort study in Taiwan.” Medicine (2025). PMID: 40388720 ↗

    L2COHORTCited in: Interventional and Device Therapy
  185. [185]

    Wu P, Kiram A, Zhu Y et al.. “Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis.” Metabolism: clinical and experimental (2026). PMID: 42225205 ↗

    L5OTHERCited in: Interventional and Device Therapy
  186. [186]

    Wang X, Song Y, Zhao W et al.. “Cinnamaldehyde mitigates MASLD through SIRT1/FOXO1-induced autophagy and synergistic gut microbiota modulation.” NPJ science of food (2026). PMID: 41957048 ↗

    L5OTHERCited in: Interventional and Device Therapy
  187. [187]

    Williams ZE, Singh I, Marks N et al.. “Innovative wound management of refractory venous ulcers with topical oxygen therapy.” Journal of vascular surgery. Venous and lymphatic disorders (2026). PMID: 41864536 ↗

    L4OTHERCited in: Interventional and Device Therapy
  188. [188]

    Zhang Y, Teng M, He W et al.. “4-Hydroxybenzyl Alcohol Mitigates Hyperlipidemia-Associated Depression by Inhibiting Neuroinflammation via the NKIRAS2/NF-κB Pathway.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41801218 ↗

    L5OTHERCited in: Interventional and Device Therapy
  189. [189]

    Torosian K, Díaz LA, Tesfai K et al.. “Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-associated Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41679525 ↗

    L2OTHERCited in: Interventional and Device Therapy
  190. [190]

    Ding M, Xiao Z, Hou X et al.. “Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease.” Chinese medicine (2026). PMID: 41580820 ↗

    L5OTHERCited in: Interventional and Device Therapy
  191. [191]

    Ambardekar AV, Bhatt A, Hoekstra M et al.. “Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.” Journal of the American College of Cardiology (2026). PMID: 41885675 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  192. [192]

    März W, Scharnagl H, Abletshauser C et al.. “Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.” Circulation (2001). PMID: 11306521 ↗

    L1RCTCited in: History and Evolution of Treatment
  193. [193]

    Lansky AJ, Pietras C, Costa RA et al.. “Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Circulation (2005). PMID: 15811868 ↗

    L1RCTCited in: History and Evolution of Treatment
  194. [194]

    Vaduganathan M, Bhatt DL, Cryer BL et al.. “Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.” Journal of the American College of Cardiology (2016). PMID: 27012778 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  195. [195]

    Guyton JR, Brown BG, Fazio S et al.. “Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.” Journal of the American College of Cardiology (2008). PMID: 18420099 ↗

    L1RCTCited in: History and Evolution of Treatment
  196. [196]

    Nappo F, Esposito K, Cioffi M et al.. “Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.” Journal of the American College of Cardiology (2002). PMID: 11923038 ↗

    L1RCTCited in: History and Evolution of Treatment
  197. [197]

    Naoumova RP, Kindler H, Leccisotti L et al.. “Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.” Journal of the American College of Cardiology (2007). PMID: 18021872 ↗

    L1RCTCited in: History and Evolution of Treatment
  198. [198]

    Herrington DM, Werbel BL, Riley WA et al.. “Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.” Journal of the American College of Cardiology (1999). PMID: 10362210 ↗

    L1RCTCited in: History and Evolution of Treatment
  199. [199]

    Blake GJ, Albert MA, Rifai N et al.. “Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial.” European heart journal (2003). PMID: 14563343 ↗

    L1RCTCited in: History and Evolution of Treatment
  200. [200]

    Austin MA, McKnight B, Edwards KL et al.. “Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study.” Circulation (2000). PMID: 10859281 ↗

    L2COHORTCited in: History and Evolution of Treatment
  201. [201]

    Jenkins DJ, Wolever TM, Rao AV et al.. “Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol.” The New England journal of medicine (1993). PMID: 8389421 ↗

    L1RCTCited in: History and Evolution of Treatment
  202. [202]

    Ridker PM, Rifai N, Clearfield M et al.. “Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.” The New England journal of medicine (2001). PMID: 11430324 ↗

    L1RCTCited in: History and Evolution of Treatment
  203. [203]

    Walsh JM, Pignone M. “Drug treatment of hyperlipidemia in women.” JAMA (2004). PMID: 15138247 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  204. [204]

    Szapary PO, Wolfe ML, Bloedon LT et al.. “Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.” JAMA (2003). PMID: 12915429 ↗

    L1RCTCited in: History and Evolution of Treatment
  205. [205]

    Esposito K, Giugliano F, Di Palo C et al.. “Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial.” JAMA (2004). PMID: 15213209 ↗

    L1RCTCited in: History and Evolution of Treatment
  206. [206]

    Ballantyne CM, Podet EJ, Patsch WP et al.. “Effects of cyclosporine therapy on plasma lipoprotein levels.” JAMA (1989). PMID: 2733125 ↗

    L2RCTCited in: History and Evolution of Treatment
  207. [207]

    Esposito K, Pontillo A, Di Palo C et al.. “Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.” JAMA (2003). PMID: 12684358 ↗

    L1RCTCited in: History and Evolution of Treatment
  208. [208]

    Jenkins DJ, Jones PJ, Lamarche B et al.. “Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.” JAMA (2011). PMID: 21862744 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History
  209. [209]

    Brass EP. “Changing the status of drugs from prescription to over-the-counter availability.” The New England journal of medicine (2001). PMID: 11556302 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  210. [210]

    Ridker PM, Hennekens CH, Rifai N et al.. “Hormone replacement therapy and increased plasma concentration of C-reactive protein.” Circulation (1999). PMID: 10449692 ↗

    L4OTHERCited in: History and Evolution of Treatment
  211. [211]

    Beaumont V, Lemort N, Beaumont JL. “Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases.” European heart journal (1991). PMID: 1782953 ↗

    L3OTHERCited in: History and Evolution of Treatment
  212. [212]

    Ahmad A, Khan M, Ghayyad K et al.. “Statin therapy is not associated with inferior postoperative outcomes after arthroscopic rotator cuff repair: a systematic review and meta-analysis.” Journal of shoulder and elbow surgery (2026). PMID: 42173477 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, Prognosis and Natural History
  213. [213]

    Jia D, Wang H, Jiang W et al.. “A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.” Frontiers in immunology (2026). PMID: 42079612 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  214. [214]

    Song X, Hu Y, Chen Y. “Uterine fibroids detected in early pregnancy and their association with adverse pregnancy outcomes: a single-centre retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42026504 ↗

    L4COHORTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  215. [215]

    Fancher A, Lopez-Candales A, Sawalha K. “Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management.” Journal of lipid and atherosclerosis (2025). PMID: 42211141 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  216. [216]

    Wang L, Niu Y, Wang L. “Pontine infarction isolated to trigeminal sensory fibers: a case report.” Frontiers in pain research (Lausanne, Switzerland) (2026). PMID: 42317569 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  217. [217]

    Arias-Romero J, Mambetsariev I, Fricke J et al.. “Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.” Translational lung cancer research (2026). PMID: 42291351 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  218. [218]

    Bauer RC, Tohyama J, Cui J et al.. “Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.” Circulation (2015). PMID: 25712206 ↗

    L5OTHERCited in: Complications
  219. [219]

    Coberly EA, Hammer RD. “Images in clinical medicine: Morphologic changes in erythrocytes in hypertriglyceridemia.” The New England journal of medicine (2014). PMID: 25119625 ↗

    L4CASE_REPORTCited in: Complications
  220. [220]

    Zhang J, Hu Z, Song C et al.. “Hemoglobin glycation index correlates with the prognoses of critically ill patients with hyperlipidemia: a retrospective cohort study from the MIMIC-IV database.” BMC endocrine disorders (2026). PMID: 42168947 ↗

    L4COHORTCited in: Complications, Prognosis and Natural History
  221. [221]

    Zulfa IM, Risni HW, Brauer R et al.. “Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.” Postgraduate medicine (2026). PMID: 42357832 ↗

    L1SR_OBSCited in: Complications
  222. [222]

    Zeng C, Lyu H, Lou L et al.. “Association between stress hyperglycemic ratio and stroke in older people with metabolic syndrome: a prospective cohort study from UK Biobank.” Frontiers in endocrinology (2026). PMID: 42051452 ↗

    L2COHORTCited in: Prognosis and Natural History
  223. [223]

    Lee YJ, Lee JH, Kim M et al.. “Combined Pre-Hypertension, Pre-Diabetes, and Pre-Hyperlipidemia and Long-Term Cardiovascular Risk in Young Adults: A Nationwide Cohort Study.” European journal of preventive cardiology (2026). PMID: 42044147 ↗

    L2COHORTCited in: Prognosis and Natural History
  224. [224]

    Nourollahpour Shiadeh M, Pakdaman K, Esmaeilnia Shirvani A et al.. “Global incidence and risk factors of pregnancy-related stroke: a systematic review and meta-analysis of over 270 million women.” BMC pregnancy and childbirth (2025). PMID: 41419807 ↗

    L1SR_OBSCited in: Special Populations and Prevention
  225. [225]

    Yan C, Shen X, Han S et al.. “Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study.” Journal of translational medicine (2026). PMID: 41782035 ↗

    L2COHORTCited in: Special Populations and Prevention
  226. [226]

    Camara J, Tsujiguchi H, Hara A et al.. “Chronic pain and mortality risk among middle-age and older Japanese: the Shika town cohort study.” Pain reports (2025). PMID: 41244944 ↗

    L2COHORTCited in: Special Populations and Prevention
  227. [227]

    Chen Y, Huang L, Hu T et al.. “The changing trend of hepatitis B virus carrier rate with different combinations of hepatitis B virus markers and their impact on maternal perinatal characteristics and pregnancy outcomes: a multicenter retrospective cohort study.” Virology journal (2025). PMID: 41214772 ↗

    L3COHORTCited in: Special Populations and Prevention
  228. [228]

    Naim MAAZ, Sumida K, Streja E et al.. “Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol.” Drugs (2026). PMID: 41528633 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  229. [229]

    Hsiao PJ, Tsou LL, Yang CC et al.. “Magnesium Oxide Use and Clinical Outcomes in CKD Patients: Evidence from a Nationwide Population-Based Cohort Study in Taiwan.” International journal of medical sciences (2026). PMID: 41938509 ↗

    L3COHORTCited in: Special Populations and Prevention
  230. [230]

    Delbari A, Akbarzadeh I, Bidkhori M et al.. “The Prevalence and Associated Factors of Smoking and Smoking-Cessation in Iranian Older Adults: Ardakan Cohort Study on Aging (ACSA).” Substance use & misuse (2026). PMID: 41782359 ↗

    L4COHORTCited in: Special Populations and Prevention
  231. [231]

    You X, Xu Y, Zhao J et al.. “The association of geriatric nutritional risk and perioperative anesthesia-related adverse reactions in elderly patients with colorectal cancer-a prospective study.” Translational cancer research (2025). PMID: 41234882 ↗

    L2COHORTCited in: Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…